Physician profile
David Mintz
NPI 1902326200
$1,735.45
in general payments reported to CMS, 2019-2025
21 companies · $972 in 2025
The $972 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.75 · 2022: $446 · 2024: $284 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $425.21 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Merck Sharp & Dohme LLC | $173.87 | 2024-2025 | Winrevair, Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.46 | 2024-2025 | Jardiance |
| Amgen INC. | $156.16 | 2022-2025 | Repatha |
| Alnylam Pharmaceuticals INC. | $123.03 | 2024-2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $117.15 | 2024-2025 | Uptravi, Opsumit |
| Astellas Pharma US INC | $99.00 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.39 | 2024-2025 | Lifevest |
| Bridgebio Pharma, INC. | $57.00 | 2025 | Attruby |
| Pfizer INC. | $50.57 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.44 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $37.81 | 2024-2025 | Farxiga |
| Scpharmaceuticals INC. | $34.48 | 2025 | |
| Cvrx, INC. | $27.58 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $25.64 | 2024 | Xarelto |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.49 | 2025 | Latitude Communicator Power Supply |
| Impulse Dynamics (USA) INC. | $23.38 | 2025 | Optimizer |
| Abiomed | $20.28 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $16.53 | 2024 | |
| United Therapeutics Corporation | $16.44 | 2024 | Remodulin, Orenitram |
| Medtronic, INC. | $15.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mintz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.